Cargando…
Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats
BACKGROUND: After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. We hypothesized that unlike nitric oxide (NO)-agents, L-NAME and/or L-arginine, the application of the stable gastric...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667405/ https://www.ncbi.nlm.nih.gov/pubmed/33251034 http://dx.doi.org/10.4292/wjgpt.v11.i5.93 |
_version_ | 1783610306090500096 |
---|---|
author | Cesar, Lidija Berkopic Gojkovic, Slaven Krezic, Ivan Malekinusic, Dominik Zizek, Helena Batelja Vuletic, Lovorka Petrovic, Andreja Horvat Pavlov, Katarina Drmic, Domagoj Kokot, Antonio Vlainic, Josipa Seiwerth, Sven Sikiric, Predrag |
author_facet | Cesar, Lidija Berkopic Gojkovic, Slaven Krezic, Ivan Malekinusic, Dominik Zizek, Helena Batelja Vuletic, Lovorka Petrovic, Andreja Horvat Pavlov, Katarina Drmic, Domagoj Kokot, Antonio Vlainic, Josipa Seiwerth, Sven Sikiric, Predrag |
author_sort | Cesar, Lidija Berkopic |
collection | PubMed |
description | BACKGROUND: After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. We hypothesized that unlike nitric oxide (NO)-agents, L-NAME and/or L-arginine, the application of the stable gastric pentadecapeptide BPC 157 with its most recent vascular effects (“vascular recruitment”) means attenuated bowel adhesion formation and NO- and malondialdehyde (MDA)-tissue values. AIM: To focused on the bowel adhesion and the therapy with the BPC 157, its most and application of NO-agents. METHODS: Along with defect creation, medication was (1) during surgery, once, at 1 min after defect creation as an abdominal bath (1 mL/rat), BPC 157 (10 µg/kg, 10 ng/kg, 1 mL/rat), an equivolume of saline, L-NAME (5 mg/kg), L-arginine (200 mg/kg) alone and/or combined. Alternatively, medication was (2) intraperitoneally once daily, first application at 30 min after surgery, last application 24 h before assessment at d 7 or d 14. As a postponed therapy to pre-existing adhesion (3), BPC 157 (10 µg/kg, 10 ng/kg intraperitoneally, 1 mL/rat) was given once daily since d 7. RESULTS: The recovery effect of the BPC 157 regimens goes with the presence of abundant vascular vessels in and near the defect, which occurs rapidly. Lastly, also applied as post-treatment, BPC 157 creates attenuated adhesions, minimal or no adhesion. Contrarily, NO-agents have diverse initial and final effects: The initial weakening of blood vessel disappearance and finally, severe worsening of adhesions (L-NAME) vs the initial weakening of blood vessel disappearance and finally, attenuation of adhesions formation (L-arginine), which counteract each other response given together. Importantly, BPC 157 maintains its beneficial effect also when given with NO-agents (L-NAME + BC 157; L-arginine + BPC 157; L-NAME + L-arginine + BPC 157). Finally, with respect to the increased NO- and MDA- values-adhesion tissue formation relation, unlike diverse effect of the NO-agents, the BPC 157 application effect regularly combines decrease on the increased NO- and MDA- values and the beneficial outcome (less adhesion formation). CONCLUSION: BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation. |
format | Online Article Text |
id | pubmed-7667405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-76674052020-11-27 Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats Cesar, Lidija Berkopic Gojkovic, Slaven Krezic, Ivan Malekinusic, Dominik Zizek, Helena Batelja Vuletic, Lovorka Petrovic, Andreja Horvat Pavlov, Katarina Drmic, Domagoj Kokot, Antonio Vlainic, Josipa Seiwerth, Sven Sikiric, Predrag World J Gastrointest Pharmacol Ther Basic Study BACKGROUND: After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. We hypothesized that unlike nitric oxide (NO)-agents, L-NAME and/or L-arginine, the application of the stable gastric pentadecapeptide BPC 157 with its most recent vascular effects (“vascular recruitment”) means attenuated bowel adhesion formation and NO- and malondialdehyde (MDA)-tissue values. AIM: To focused on the bowel adhesion and the therapy with the BPC 157, its most and application of NO-agents. METHODS: Along with defect creation, medication was (1) during surgery, once, at 1 min after defect creation as an abdominal bath (1 mL/rat), BPC 157 (10 µg/kg, 10 ng/kg, 1 mL/rat), an equivolume of saline, L-NAME (5 mg/kg), L-arginine (200 mg/kg) alone and/or combined. Alternatively, medication was (2) intraperitoneally once daily, first application at 30 min after surgery, last application 24 h before assessment at d 7 or d 14. As a postponed therapy to pre-existing adhesion (3), BPC 157 (10 µg/kg, 10 ng/kg intraperitoneally, 1 mL/rat) was given once daily since d 7. RESULTS: The recovery effect of the BPC 157 regimens goes with the presence of abundant vascular vessels in and near the defect, which occurs rapidly. Lastly, also applied as post-treatment, BPC 157 creates attenuated adhesions, minimal or no adhesion. Contrarily, NO-agents have diverse initial and final effects: The initial weakening of blood vessel disappearance and finally, severe worsening of adhesions (L-NAME) vs the initial weakening of blood vessel disappearance and finally, attenuation of adhesions formation (L-arginine), which counteract each other response given together. Importantly, BPC 157 maintains its beneficial effect also when given with NO-agents (L-NAME + BC 157; L-arginine + BPC 157; L-NAME + L-arginine + BPC 157). Finally, with respect to the increased NO- and MDA- values-adhesion tissue formation relation, unlike diverse effect of the NO-agents, the BPC 157 application effect regularly combines decrease on the increased NO- and MDA- values and the beneficial outcome (less adhesion formation). CONCLUSION: BPC 157 therapy can be suited for the realization of the peritoneal defect healing with minimal or no adhesion formation. Baishideng Publishing Group Inc 2020-11-08 2020-11-08 /pmc/articles/PMC7667405/ /pubmed/33251034 http://dx.doi.org/10.4292/wjgpt.v11.i5.93 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Basic Study Cesar, Lidija Berkopic Gojkovic, Slaven Krezic, Ivan Malekinusic, Dominik Zizek, Helena Batelja Vuletic, Lovorka Petrovic, Andreja Horvat Pavlov, Katarina Drmic, Domagoj Kokot, Antonio Vlainic, Josipa Seiwerth, Sven Sikiric, Predrag Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title | Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title_full | Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title_fullStr | Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title_full_unstemmed | Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title_short | Bowel adhesion and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine in rats |
title_sort | bowel adhesion and therapy with the stable gastric pentadecapeptide bpc 157, l-name and l-arginine in rats |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667405/ https://www.ncbi.nlm.nih.gov/pubmed/33251034 http://dx.doi.org/10.4292/wjgpt.v11.i5.93 |
work_keys_str_mv | AT cesarlidijaberkopic boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT gojkovicslaven boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT krezicivan boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT malekinusicdominik boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT zizekhelena boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT bateljavuleticlovorka boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT petrovicandreja boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT horvatpavlovkatarina boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT drmicdomagoj boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT kokotantonio boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT vlainicjosipa boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT seiwerthsven boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats AT sikiricpredrag boweladhesionandtherapywiththestablegastricpentadecapeptidebpc157lnameandlarginineinrats |